Cash Injection Puts Quell At Forefront Of Treg Therapy
Series B Raises $156m
Executive Summary
The London-based biotech is hoping to turn the dream of liver organ transplant without the need for lifelong immunosuppression into reality.
You may also be interested in...
Investors Impressed With Dualyx Tregs Plans
The proceeds from the series A will be used to progress Dualyx’s preclinical program DT-001, which targets "the highly attractive TNF receptor 2 (TNFR2), widely regarded as a master control switch in immune modulation."
Helping Universities Avoid The Pitfalls Of Biotech Spin-offs
Universities and venture capital firms have produced guidance that they hope will accelerate and support the founding of a new generation of start-ups.
With $120m, HI-Bio Aims To Rapidly Prove Approach To Immune-Mediated Diseases
Human Immunology Biosciences (HI-Bio) launched with $120m and two candidates from MorphoSys, including the CD38 inhibitor felzartamab already in the clinic for immune-mediated kidney diseases.